Neurofibromatosis
MONDO:0021061A hereditary neoplastic syndrome in which tumors grow in the nervous system. There are typically 3 main types recognized, but other forms with uncertain etiology exist.
Also known as: Recklinghausen's neurofibromatosis, acoustic neurofibromatosis, central Neurofibromatosis, neurofibromatosis, neurofibromatosis syndrome, peripheral Neurofibromatosis, type IV neurofibromatosis of riccardi, von Reklinghausen disease
125 clinical trials for this condition and its sub-types, 19 tagged with Neurofibromatosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Neurofibromatosis
-
Neurofibromatosis type 1 73 trials
3 sub-types
-
NF2-related schwannomatosis 21 trials
-
Schwannomatosis 3 trials
4 sub-types
- 22q-related schwannomatosis 0 trials
- LZTR1-related schwannomatosis 0 trials
- SMARCB1-related schwannomatosis 0 trials
- Neurofibromatosis, type III, mixed central and peripheral 0 trials
-
Neurofibromatosis-Noonan syndrome 2 trials
1 sub-type
- Watson syndrome 0 trials
-
Can a Two-Drug combo stop a rare, aggressive nerve tumor?
Disease control Not yet recruitingThis phase 2 trial is testing whether the combination of avutometinib and defactinib can stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery. The study enrolls people over 12 years old with relapsed, refractory, met…
Phase 2 • Sponsor: Girish Dhall, MD • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New platform trial takes on NF2 tumors with multiple drug strategies
Disease control Not yet recruitingThis trial tests several drugs in people with NF2-related schwannomatosis, a condition that causes tumors on nerves and in the brain. The study uses a flexible 'platform' design to evaluate treatments for four tumor types: vestibular schwannomas, non-vestibular schwannomas, menin…
Phase 2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
Disease control Not yet recruitingThis trial tests the drug selumetinib in people with NF2-related schwannomatosis, a genetic condition that causes non-cancerous tumors on nerves, often leading to hearing loss. The study includes both adults and children whose tumors cannot be surgically removed or are growing. R…
Phase 2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Drug combo aims to shrink NF2 tumors and save hearing
Disease control Not yet recruitingThis trial tests whether combining two drugs—luvometinib (a targeted therapy) and serplulimab (an immunotherapy)—can shrink tumors and improve hearing in people with NF2-related schwannomatosis. Participants have progressive vestibular schwannomas or meningiomas that are not suit…
Phase 1/2 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo aims to tackle tough brain tumors in NF1 patients
Disease control Not yet recruitingThis phase 2 trial tests the drug mirdametinib, alone or with radiation, in people with NF1-related high-grade gliomas (aggressive brain tumors). It includes three groups: those with recurrent sporadic glioblastoma, newly diagnosed NF1-associated glioblastoma, and other NF1-relat…
Phase 2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill aims to shrink tumors in rare nerve disorder
Disease control Not yet recruitingThis early-phase trial tests an oral drug called Trineumin (PRG-N-01) in 25 adults with neurofibromatosis type II (NF2), a genetic condition that causes non-cancerous tumors on nerves. The study has two parts: first finding a safe dose, then checking if that dose can shrink tumor…
Phase 1/2 • Sponsor: PRG Science & Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Rewiring the brain to silence chronic pain — a bold psychological therapy is put to the test
Symptom relief Not yet recruitingThis trial tests whether pain reprocessing therapy (PRT) — a brief psychological treatment that combines education, cognitive restructuring, and body-focused techniques — can reduce chronic pain. Adults with persistent pain lasting over three months are randomly assigned to full …
Sponsor: Ben-Gurion University of the Negev • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Patients and staff team up to redesign hospital clinics for sensory needs
Knowledge-focused Not yet recruitingThis project at King's College London asks how hospital outpatient departments can work better for people with neurofibromatosis who also have sensory challenges. About 30 patients, carers, and staff from Guy's and St Thomas' NHS Foundation Trust take part in interviews, observat…
Sponsor: King's College London • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New online tool aims to help families uncover hidden cancer risks
Knowledge-focused Not yet recruitingThis study tests whether a new online program can help families understand their inherited cancer risk and encourage relatives to get low-cost genetic testing. Researchers will enroll 400 adults who carry a cancer-related gene change and their family members. The goal is to see i…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Can a simple walk test spot motor trouble in kids with NF1?
Knowledge-focused Not yet recruitingThis study looks at how young children with neurofibromatosis type 1 (NF1) walk, to see if simple walking tests can help doctors spot and predict movement problems early. Researchers will measure walking speed and other skills in 56 children under 6 years old. The goal is to crea…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC